The U.S. Food and Drug Administration (FDA) has approved donidalorsen — to be marketed Dawnzera — as a prophylactic treatment for swelling attacks in adults and adolescents, ages 12 and older, with hereditary angioedema (HAE). With this decision, Dawnzera has become the first and only RNA-targeted therapy approved for…
A woman in her 30s who experienced recurrent, nonspecific gastrointestinal symptoms was diagnosed with angioedema of the small intestine — also known as intestinal angioedema, or sometimes angioedema of the bowel — related to the use of an angiotensin-converting enzyme (ACE) inhibitor to treat high blood pressure, according to…
Navenibart, an experimental treatment from Astria Therapeutics to prevent swelling episodes in people with hereditary angioedema (HAE), continues to show strong and sustained benefits in a long-term clinical trial. New data from the ALPHA-SOLAR Phase 2 (NCT06007677) open-label extension study show treatment with navenibart every three…
The oral medication Orladeyo (berotralstat) is now approved in Colombia as a preventive treatment to reduce the risk of swelling attacks in people with hereditary angioedema (HAE), ages 12 and older. The approval, from Colombia’s National Institute of Drug and Food Surveillance (INVIMA), follows the therapy’s approval in…
The prevalence of certain conditions — namely, allergies, autoimmune diseases, and asthma — is higher among people with hereditary angioedema (HAE) than in the general population, according to a new study from Canada. The data specifically showed that the proportion of HAE patients who reported having autoimmune conditions was…
A Phase 3 clinical trial testing sebetralstat as an on-demand treatment for swelling attacks in children with hereditary angioedema (HAE) has completed enrollment a year ahead of schedule. The trial’s initial target enrollment was surpassed in less than seven months, according to KalVista Pharmaceuticals, which is developing…
The symptoms of hereditary angioedema (HAE) can be very hard on adolescents, significantly affecting their health-related quality of life, particularly in regard to schooling and their social and emotional well-being, a U.S. study based on interviews with a dozen young patients reported. Those taking part, ages 12 to 17…
An oral granule formulation of Orladeyo (berotralstat) was safe and well tolerated, and able to reduce the rates of swelling attacks in children with hereditary angioedema (HAE), according to an interim analysis of an ongoing Phase 3 trial. The open-label Phase 3 APeX-P trial (NCT05453968) is assessing the…
Despite being on prophylatic, or preventive, treatment, people with hereditary angioedema (HAE) report similar struggles in managing and recovering from acute attacks to those using on-demand therapy alone, a new survey study in the U.S. has revealed. The researchers noted that anxiety levels among patients when anticipating the use…
Diet and physical activity may trigger swelling attacks in people with hereditary angioedema (HAE), according to a patient survey study conducted in Germany. About a third of patients surveyed experienced swelling attacks related to the consumption of certain foods, including fruits, vegetables, bread, or dairy products, while some…
Get regular updates to your inbox.
